JBT Marel (NYSE:JBTM) continues expanding food processing technology following Russell benchmark changes, supported by ...
Explore OFG Bancorp operations, banking services, lending activities, digital platforms, and Puerto Rico presence within the ...
ARVO presenters conducted a retrospective study to assess the visual and anatomical outcomes of patients receiving complement inhibitors for geographic atrophy. In a real-world cohort of patients with ...
Abstract: Classical fuzzy complement functions compute the non-membership grades of elements based solely on their membership values. However, they often fall short in effectively representing ...
Maddy Buxton, Culture & Trends manager at YouTube, discusses how creators and digital animation on the platform are global, fan-driven, popular among young adults, and driving innovation and ...
Recently, Environmental Protection Agency Administrator Lee Zeldin announced the end of federal credits for automakers that install start/stop systems, part of a broader overhaul of greenhouse gas ...
The FDA has requested that Amgen voluntarily withdraw avacopan (Tavneos), a treatment for anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis, but the company said it has no plans to ...
— Initial Orders Received and Fulfilled from Multiple Transplant Centers, with YARTEMLEA Now Administered to Both Adult and Pediatric Patients with TA-TMA — YARTEMLEA is the first and only approved ...
The FDA has approved Omeros' Yartemlea as the first treatment for hematopoietic stem cell transplant-associated thrombotic microangiopathy. It is the first FDA nod for the 31-year-old Seattle biotech.
(RTTNews) - Omeros Corporation (OMER) today announced that the FDA has approved YARTEMLEA for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy in adults and ...
SEATTLE--(BUSINESS WIRE)-- Omeros Corporation (NASDAQ: OMER) today announced that the U.S. Food and Drug Administration (FDA) has approved YARTEMLEA® (narsoplimab-wuug) for the treatment of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results